HOSPITAL-ACQUIRED DISEASE TESTING MARKET ANALYSIS

Market Challenges And Opportunities

Increasing instance of hospital acquired infections is expected to propel the market growth over the forecast period

Rising incidence of infections such as central line associated bloodstream infection (CLABSI), catheter-related bloodstream infection (CRBSI), and others are expected to drive growth of the hospital-acquired disease testing market over the forecast period. For instance, according to data published during the National Healthcare Safety Network Bloodstream Infection Surveillance in March 2018, around 30,000 CLABSI cases are reported every year in the U.S. CLABSI can prolong the hospital stay, which can increase the cost burden on patients and also lead to mortality.

Increasing launches of advanced and efficient testing tools and kits are expected to fuel the growth of the hospital-acquired disease testing market

Manufacturers are focusing on development of advanced testing kits to enhance the efficiency of hospital-acquired disease diagnosis. For instance, in December 2019, F.Hoffmann-La Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval for cobas vivoDx MRSA, a diagnostic test designed to detect the Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. The approval of cobas vivoDx MRSA is intended to aid in the control and prevention of the Methicillin-resistant Staphylococcus aureus (MRSA) infections in healthcare settings.

However, decreasing prevalence of nosocomial infections due to the availability of advanced hospital-acquired disease tests in developed countries is likely to hinder the market growth in the near future.